# Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

> **NCT02246920** · PHASE3 · TERMINATED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 1474 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Fluticasone propionate
- **DRUG:** Flonase®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02246920
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03-01
- **Primary completion:** 2014-07-14
- **Final completion:** 2014-07-14
- **Target enrollment:** 1474 (ACTUAL)
- **Why stopped:** Development Halted
- **Last updated:** 2023-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02246920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02246920, "Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02246920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*